Cabaletta Bio, Inc. (CABA): Shareholders' Equity
$112.05M
As of 2025-12-31
$210.59M
As of 2026-06-30
+2.3%
3-year compound annual growth
+0.5%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $112.05M | -26.4% | 2026-03-23, Balance as of period end |
| 2024-12-31 | $152.34M | -35.5% | 2026-03-23, Balance as of period end |
| 2023-12-31 | $236.20M | +126.0% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $104.52M | -11.4% | 2024-03-21, Balance as of period end |
| 2021-12-31 | $117.96M | +7.7% | 2023-03-16, Balance as of period end |
| 2020-12-31 | $109.54M | -20.8% | 2022-03-17, Balance as of period end |
| 2019-12-31 | $138.32M | n/m | 2021-03-16, Balance as of period end |
| 2018-12-31 | -$10.69M | n/a | 2020-03-30, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | 2025-12-31 | $112.05M | -26.4% |
| Aura Biosciences, Inc. (AURA) | 2025-12-31 | $136.91M | -9.9% |
| SAB Biotherapeutics, Inc. (SABS) | 2025-12-31 | $151.49M | +483.4% |
| Sutro Biopharma, Inc. (STRO) | 2025-12-31 | -$132.45M | n/m |
| Compugen Ltd (CGEN) | 2025-12-31 | $102.73M | +87.1% |
| Caribou Biosciences, Inc. (CRBU) | 2025-12-31 | $122.17M | -51.7% |
| Precision Biosciences Inc (DTIL) | 2025-12-31 | $92.25M | +63.6% |
| ImageneBio, Inc. (IMA) | 2025-12-31 | $133.14M | n/m |
| Inhibikase Therapeutics, Inc. (IKT) | 2025-12-31 | $172.90M | +82.3% |
Compare CABA, AURA, SABS, STRO side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗